Arabs represent about 5% of the world population and are massively underrepresented in genomic studies worldwide, yet minimal efforts have been made to date to understand clinical utility of polygenic scores in this group.
Celiac Disease Program
Charles River Plaza
165 Cambridge Street, 9th Floor
Boston, MA 02114
Hours: Monday–Friday, 8:00 am–5:00 pm
Services also available at:
Mass General North Shore Center for Outpatient Care
102-104 Endicott Street
Danvers, MA 01923
Explore This Program
A Multidisciplinary Approach to Care
The prevalence of celiac disease in the U.S. has quadrupled over the past 50 years. The Celiac Disease Program at Mass General brings together an expert team of providers who work with patients with celiac disease to co-create health.
This multi-disciplinary care team is tailored to each patient’s unique condition. Our providers include:
- GI pathologists
- GI radiologists
- Food allergy specialists
We offer the full range of endoscopic diagnostic procedures critical for obtaining a tissue diagnosis and differentiating celiac disease from other disorders such as inflammatory bowel disease (Crohn's disease and ulcerative colitis), microscopic colitis (lymphocytic and collagenous), eosinophilic and autoimmune enteritis, and irritable bowel syndrome (IBS).
Patient Education and Support
Patient education and support are important components of our mission. We are committed to helping patients understand their disease, assess their treatment options, participate in their treatment decisions and feel in control of their disease. Our physicians are experienced in fine-tuning medical therapies and helping patients obtain relief from persistent, difficult-to-manage symptoms.
To help educate the community about how our diet, lifestyle and environment can affect GI health, our doctors participate in community events throughout the year.
Advancing an Understanding of Celiac Disease through Ongoing Research
The Celiac Disease Program at Mass General is a comprehensive program dedicated to the diagnosis and treatment of patients with celiac disease and all gluten-mediated disorders. The gastroenterology department at Massachusetts General Hospital is consistently ranked among the nation's top programs, with Magnet award-winning nurses providing patients with compassionate, timely care. Magnet designation represents the highest honor available for nursing excellence and is achieved by fewer than 7% of hospitals in the United States. Our multidisciplinary team of providers has been recognized both nationally and internationally for groundbreaking research and outstanding patient care.
We believe that each patient can significantly improve our knowledge of celiac disease and contribute toward understanding the factors that influence the development of this disease and factors that determine response to treatments. All of the physicians involved in the Celiac Disease Program actively participate in research programs aimed at understanding the underlying cause of celiac disease, with the goal of developing more effective treatment approaches.
Dr. Ramnik Xavier directs a research program that focuses on understanding the genetic basis of celiac disease based on genome-wide association studies. Dr. Xavier's research group actively collaborates with the lab of Dr. Cisca Wijmenga, a world leader in the genetics of celiac disease. In addition, Dr. Xavier works closely with Dr. Bana Jabri, a renowned immunologist who is working with Dr. Xavier to develop systems biology approaches to understanding the fundamental mechanisms underlying celiac disease.
Related News and Articles
- Oct | 16 | 2023
Florez now oversees the largest clinical and research department at Mass General, with 10 clinical divisions, seven research centers/units, and 19 training programs comprising over 1,000 faculty members, 900 trainees and 100 medical practices.
- Sep | 20 | 2023
Research Spotlight: Population Health Impact, Cost-Effectiveness, and Affordability of Community-Based HIV Treatment and Monitoring in South Africa: A Health Economics Modelling Study
A modeling study projects that by 2060, community-based HIV treatment and monitoring averts 28% of HIV-related deaths and 28% of new infections.
- Press Release
- Aug | 10 | 2023
Transplant Recipients Experience Limited Protection With Primary COVID-19 Vaccination Series, but Third Dose Boosts Response
For lung and heart transplant recipients, vaccine doses beyond the third dose are likely important for maintaining immunity.
- Press Release
- Aug | 7 | 2023
Method will help clinicians monitor and treat critically ill patients.
- Press Release
- Jul | 28 | 2023
Identification of Genetic Drivers for Esophageal Cancer Creates New Opportunity for Screening, Treatment
Mass General Cancer Center investigators found that nine percent of esophageal adenocarcinoma patients harbor mutations in cancer-predisposing genes, shedding light on the causes of progression to the disease and new possibilities for screening and treatment.